The Outcome for Patients With Pathologic Node-Positive Prostate Cancer Treated With Intensity Modulated Radiation Therapy and Androgen Deprivation Therapy: A Case-Matched Analysis of pN1 and pN0 Patients.
Improved outcome is reported after surgery or external beam radiation therapy (EBRT) plus androgen deprivation therapy (ADT) for patients with lymph node (LN) positive (N1) prostate cancer (PC). Surgical series have shown that pathologic (p)N1 PC does not behave the same in all patients. The aim of this study was to perform a matched-case analysis to compare the outcome of pN1 and pN0 PC after high-dose EBRT plus ADT.



Radiation therapy up to 80 Gy was delivered to the prostate with a minimal dose of 45 Gy to the pelvis for pN1 patients. After matching, Kaplan-Meier statistics were used to compare the 5-year biochemical and clinical relapse-free survival (bRFS and cRFS), prostate cancer-specific survival (PCSS), and overall survival (OS). Acute and late rectal and urinary toxicity was evaluated.



Sixty-nine pN1 PC patients were matched 1:1 with pN0 PC patients. The median follow-up time was 60 months. The 5-year bRFS and cRFS for pN1 versus pN0 PC patients were 65% ± 7% versus 79% ± 5% (P=.08) and 70% ± 6% versus 83% ± 5% (P=.04) respectively. No significant difference was found in bRFS or cRFS rates between low volume pN1 (≤2 positive LNs) and pN0 patients. The 5-year PCSS and OS were comparable between pN1 and pN0 PC patients: PCSS: 92% ± 4% versus 93% ± 3% (P=.66); OS: 82% ± 5% versus 80% ± 5% (P=.58). Severe toxicity was rare for both groups, although pN1 patients experienced significantly more acute grade 2 rectal toxicity.



Primary EBRT plus 2 to 3 years of ADT is a legitimate treatment option for pN1 PC patients, especially those with ≤2 positive LNs, and this with bRFS and cRFS rates comparable to those in pN0 PC patients. For pN1 PC patients with >2 positive LNs, bRFS and cRFS are worse than in pN0 patients, but even in this subgroup, long-term disease control is obtained.
Department of Urology, Ghent University Hospital, Ghent, Belgium.
Annelies
A
Van Hemelryk
Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium.
Gert
G
De Meerleer
Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium.
Piet
P
Ost
Department of Urology, Ghent University Hospital, Ghent, Belgium.
Filip
F
Poelaert
Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium.
Werner
W
De Gersem
Department of Urology, Ghent University Hospital, Ghent, Belgium.
Karel
K
Decaestecker
Department of Radiology, Ghent University Hospital, Ghent, Belgium.
Pieter
P
De Visschere
Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium. Electronic address: valerie.fonteyne@uzgent.be.
Valérie
V
Fonteyne
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use*; D001530:Belgium / Q000453:epidemiology; D016022:Case-Control Studies; D059248:Chemoradiotherapy / Q000401:mortality; D018572:Disease-Free Survival; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011471:Prostatic Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D011832:Radiation Injuries / Q000401:mortality*; D050397:Radiotherapy, Intensity-Modulated / Q000401:mortality*; D012189:Retrospective Studies; D000071036:Sentinel Lymph Node / Q000473:pathology*; D015996:Survival Rate; D016896:Treatment Outcome
D000726:Androgen Antagonists